Skip to content
DraconiticResearch
Search Sources API
190,869 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BYJournal of Pharmaceutical Analysis

Nano-formulations in therapeutic strategies targeting cancer ferroptosis

  • Mingyue Zhou1
  • Jin Lan2
  • Tianyang Zhang2
  • Zhiyong Li2
  • Chongyang Ou2
  • Jun Xiong2
  • Juan Su3
  • Shuai Yan4
4 affiliations
  1. 1School of Pharmacy, Naval Medical University, Shanghai, 200433, China
  2. 2Faculty of Medical Imaging, Naval Medical University, Shanghai, 200433, China
  3. 3School of Pharmacy, Naval Medical University, Shanghai, 200433, China; Corresponding author.
  4. 4Department of Anorectal Surgery, Suzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Suzhou, Jiangsu, 215009, China; Corresponding author.
Read full textDOICite

Abstract

Ferroptosis is a cell death mode caused by excessive accumulation of lipid peroxides (LPOs) due to intracellular metabolic pathway disorder, which is closely related to intracellular iron metabolism and lipid homeostasis. In cancer therapy, this metabolic imbalance promotes the clearance of tumor cells, suggesting that ferroptosis exerts a tumor suppressor function. However, the clinical translation of ferroptosis-based strategies in oncology is currently hindered by challenges such as inadequate therapeutic efficacy. In the past five years, the rational design of nano-formulations to induce cancer ferroptosis combined with other emerging therapeutic modalities (chemotherapy (CT), chemodynamic therapy (CDT), photodynamic therapy (PDT), sonodynamic therapy (SDT), and immunotherapy) has achieved promising therapeutic effects in many rodent tumor models. This review summarizes the recent progress of novel nano-formulations for cancer ferroptosis therapy. The multiple mechanisms and detection indicators of cancer cells during ferroptosis, the rational design of novel nano-formulations, and their strategies for inducing cancer ferroptosis will be introduced. Finally, the challenges and prospects of utilizing novel nano-formulations for cancer ferroptosis therapy will be discussed.

Related

  1. Targeting ferroptosis in cancer: molecular mechanisms and emerging therapeutic strategies.
    Mansoor Khaledi, Hasti Ahani, Faezeh Rezaei Tohid +8
    Biochemistry and biophysics reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Targeting host ferroptosis in cancer cachexia: Tumor-immune triggers, tissue wasting, and the therapeutic paradox
    Yan Li, Rui Chen, Shengguang Ding
    iSciencePeer-reviewedCC BY 4.0Full textOncologyCell PressCrossrefEurope PMC
  3. Targeting minimal residual disease (MRD) in colorectal cancer: Therapeutic strategies, clinical trials, and the path toward molecular cure
    Yusuf Saleem Khan, Aisha Farhana, Hatim Adam Nagi +5
    Cancer pathogenesis and therapyPeer-reviewedCC BYFull textOncologyEurope PMCEurope PMCPMC
  4. Targeting Ferroptosis in Neurodegenerative Diseases: Therapeutic Potential and Mechanistic Insights of Traditional Chinese Medicine.
    Pan Li, Zi-Meng Qi, Jing-Zhen Wu +2
    BiologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Mitochondria-associated ferroptosis in ischemic stroke: Pathophysiological evolution, interorganelle crosstalk, and therapeutic targeting
    Mengge Zhang, Yuzhe Cai, Qianru Zeng +7
    Pharmacological ResearchPeer-reviewedCC BYFull textPharmacology & toxicologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{zhou2026nanoformulations,
  title = {{Nano-formulations in therapeutic strategies targeting cancer ferroptosis}},
  author = {Mingyue Zhou and Jin Lan and Tianyang Zhang and Zhiyong Li and Chongyang Ou and Jun Xiong and Juan Su and Shuai Yan},
  journal = {Journal of Pharmaceutical Analysis},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jpha.2026.101551},
  url = {https://doi.org/10.1016/j.jpha.2026.101551},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Nano-formulations in therapeutic strategies targeting cancer ferroptosis
AU  - Mingyue Zhou
AU  - Jin Lan
AU  - Tianyang Zhang
AU  - Zhiyong Li
AU  - Chongyang Ou
AU  - Jun Xiong
AU  - Juan Su
AU  - Shuai Yan
PY  - 2026
DA  - 2026/09/01
JO  - Journal of Pharmaceutical Analysis
DO  - 10.1016/j.jpha.2026.101551
UR  - https://doi.org/10.1016/j.jpha.2026.101551
AB  - Ferroptosis is a cell death mode caused by excessive accumulation of lipid peroxides (LPOs) due to intracellular metabolic pathway disorder, which is closely related to intracellular iron metabolism and lipid homeostasis. In cancer therapy, this metabolic imbalance promotes the clearance of tumor cells, suggesting that ferroptosis exerts a tumor suppressor function. However, the clinical translation of ferroptosis-based strategies in oncology is currently hindered by challenges such as inadequate therapeutic efficacy. In the past five years, the rational design of nano-formulations to induce cancer ferroptosis combined with other emerging therapeutic modalities (chemotherapy (CT), chemodynamic therapy (CDT), photodynamic therapy (PDT), sonodynamic therapy (SDT), and immunotherapy) has achieved promising therapeutic effects in many rodent tumor models. This review summarizes the recent progress of novel nano-formulations for cancer ferroptosis therapy. The multiple mechanisms and detection indicators of cancer cells during ferroptosis, the rational design of novel nano-formulations, and their strategies for inducing cancer ferroptosis will be introduced. Finally, the challenges and prospects of utilizing novel nano-formulations for cancer ferroptosis therapy will be discussed.
SN  - 2095-1779
SN  - 2214-0883
ER  -